CHADS Calculation

The current risk stratification for stroke most widely used is CHADS2. This system uses common clinical conditions to assess risk for stroke. Points are assigned, and anticoagulation is given depending on how many points the patient has:

C Congestive heart failure 1
H Hypertension: blood pressure consistently above 140/90 mmHg (or treated hypertension on medication) 1
A Age ?75 years 1
D Diabetes Mellitus 1
S2 Prior Stroke or TIA 2

This system is simple, easy to apply and used clinically. The current (5/2011) recommendations are:

0 Low risk Aspirin

1 Moderate Risk Anticoagulation (Coumadin, Pradaxa) or ASA

2 or < High Risk Anticoagulation (Coumadin, Pradaxa)

All of these strategies need adjustment for risk of serious bleeding.

There is a newer system available, the CHA2DS2-VASc score [Congestive heart failure, Hypertension, Age ?75 years (doubled), Diabetes mellitus, Stroke (doubled), Vascular disease, Age 65–74 years, Sex category] which does make it more risky to have peripheral vascular disease, be female, or be older than 75, which may refine risk.

However, the main point is that clinical factors predict risk, and those factors are what are used to determine who should get aggresive anticoagulation.

Gage BF, van Walraven C, Pearce L, et al. (2004). “Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin”. Circulation 110 (16): 2287–92. doi:10.1161/01.CIR.0000145172.55640.93. PMID 15477396. http://circ.ahajournals.org/cgi/content/full/110/16/2287.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001). “Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation”. JAMA 285 (22): 2864–70. doi:10.1001/jama.285.22.2864. PMID 11401607
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ: Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010;137:263-272.
This entry was posted in Atrial Fibrillation and tagged , . Bookmark the permalink.